These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. The thrombolysis in myocardial infarction (TIMI) trial phase I and phase IIA pilot results. Implications for nursing. Brewer-Senerchia C Prog Cardiovasc Nurs; 1988; 3(4):128-36. PubMed ID: 2974593 [No Abstract] [Full Text] [Related]
3. Comparison of tissue plasminogen activator and streptokinase in the management of acute myocardial infarction. White HD Chest; 1989 May; 95(5 Suppl):265S-269S. PubMed ID: 2495909 [TBL] [Abstract][Full Text] [Related]
4. Recombinant tissue-type plasminogen activator as a thrombolytic agent in acute myocardial infarction. Parr KL; Valentine RP; Pitts DE; Schumacher RR; Schmidt PE; Brooks-Brunn JA; Ramsden C Indiana Med; 1987 May; 80(5):460-1. PubMed ID: 2953781 [No Abstract] [Full Text] [Related]
6. [The prevention of reocclusion after thrombolysis in acute myocardial infarct: is tissue-type plasminogen activator really superior to streptokinase?]. Negrini M G Ital Cardiol; 1995 Apr; 25(4):511-5. PubMed ID: 7677921 [No Abstract] [Full Text] [Related]
7. Fibrinogen proteolysis and coagulation system activation during thrombolytic therapy. Owen J; Grossman B; Sobel J; Kudryk B Adv Exp Med Biol; 1990; 281():401-8. PubMed ID: 2129378 [No Abstract] [Full Text] [Related]
8. Coronary thrombolysis: streptokinase or recombinant tissue-type plasminogen activator? Collen D Ann Intern Med; 1990 Apr; 112(7):529-38. PubMed ID: 2107781 [TBL] [Abstract][Full Text] [Related]
9. Thrombolytic therapy for myocardial infarction: the problem, the promise and the price. Waters DD; Wiseman A CMAJ; 1988 Apr; 138(7):598-601. PubMed ID: 3128395 [No Abstract] [Full Text] [Related]
10. Thrombolysis, streptokinase, and TPA in the treatment of acute myocardial infarction. Mock MB; Chesebro JH Cardiovasc Clin; 1987; 18(1):247-57. PubMed ID: 2955892 [No Abstract] [Full Text] [Related]
11. The effects of streptokinase and tissue plasminogen activator on left ventricular function. White HD Adv Exp Med Biol; 1990; 281():383-7. PubMed ID: 2129375 [No Abstract] [Full Text] [Related]
12. Thrombolytic therapy for myocardial infarction: a perspective of clinical trialists. The GUSTO Investigators. Califf RM; Topol EJ Clin Cardiol; 1992 Mar; 15(3):143-4. PubMed ID: 1551260 [No Abstract] [Full Text] [Related]
13. New developments in thrombolytic therapy. Collen D; Gold HK Adv Exp Med Biol; 1990; 281():333-54. PubMed ID: 2129372 [TBL] [Abstract][Full Text] [Related]
14. Intravenous fibrinolytic therapy of acute myocardial infarction: new perspectives from plasminogen activators? Kasper W; Meinertz T; Just H Klin Wochenschr; 1986 Apr; 64(7):301-6. PubMed ID: 3086619 [TBL] [Abstract][Full Text] [Related]
15. GUSTO (Global Utilization of Streptokinase and Tissue plasminogen activator in Occluded arteries): logic wins at last. Bassand JP Eur Heart J; 1994 Jan; 15(1):2-4. PubMed ID: 8174579 [No Abstract] [Full Text] [Related]
16. The rt-PA versus streptokinase controversy--IV. Swan HJ J Am Coll Cardiol; 1992 Apr; 19(5):1120. PubMed ID: 1552105 [No Abstract] [Full Text] [Related]
18. Clinical trials and decisions for thrombolytic therapy in patients with acute myocardial infarction. Conti CR Clin Cardiol; 1990 May; 13(5):307-8. PubMed ID: 2112073 [No Abstract] [Full Text] [Related]
19. Enrolment in trials of thrombolysis. Geraci E Lancet; 1990 Oct; 336(8722):1069-70. PubMed ID: 1977042 [No Abstract] [Full Text] [Related]
20. What you should know about thrombolytic therapy for acute MI. Aragon D; Martin M Am J Nurs; 1993 Sep; 93(9):24-31; quiz 33. PubMed ID: 8213959 [No Abstract] [Full Text] [Related] [Next] [New Search]